Over the last eight years, the FDA has approved 36 cell and gene therapies, with many more in the pipeline. These therapies are designed to cure or dramatically ameliorate deadly or debilitating diseases, many of which are rare. However, they come with a high price tag – an average of US$1.3m per dose. The price tag, combined with uncertainty about durability, has given health payers cause for concern. Additionally, roughly 80% of patients who would be medically eligible for cell or gene therapy over the next five years have a prior diagnosis, making it difficult for traditional health (re)insurance to cover their therapy use. If these concerns are left unaddressed, access to potentially life-saving therapies could be blocked or severely curtailed.

We work with payers (re/insurers), providers (doctors / hospitals), and developers (pharma) to address these concerns and, in doing so, remove financial barriers to cell and gene therapy use.